Group A Streptococcus or GAS infection are responsible for over 1.4 million deaths each year, and this number is still increasing. Vaccination is considered as a useful approach to enhance the host immunity against infection, and it has helped to prevent and even eradicate many infectious diseases so far. Herein we developed a potent peptide-polymer based vaccine against GAS infection. Our fully synthetic peptide vaccine candidates against group A streptococcus (GAS) were composed of J8 GAS B-cell epitope alongside with a universal helper T-cell epitope PADRE. Alkyne based peptide (J8-PADRE) was conjugated with azide based polymer named poly methyl acrylate (PMA) by Copper-Catalyzed Alkyne-Azide Cycloaddition (CuAAC). PMA-P-J8 formed nanoparticle size (146±8 nm) and PDI (0.19±0.02) measured using dynamic light scattering (DLS). PMA is one of the most widely explored bio-medical polymers because of its biocompatibility. Fourteen weeks old female mice (C57BL/6) were immunized with PMA-P-J8 and positive control with additional cholera toxin B (CTB) by oral gavage. PBS was used as negative control with a single oral immunization. All groups of mice that received GAS vaccine developed anti-GAS antibodies as determined by ELISA. The addition of CTB did not result in greater anti-GAS antibody titres. In fact, mice immunized without CTB had greater anti-GAS antibody titres than mice immunized with CTB because CTB can lower the immune response to oral vaccination. The antibodies generated were opsonic against GAS clinical isolates as measured after boost immunization. Thus, we developed a simple conjugate as an effective, adjuvant-free oral peptide-based vaccine. The enhanced vaccine efficacy, lowered dose, and simple and cost-effective process should be particularly useful in developing potent peptide-based vaccines to prevent infection.